No Data
US Stock MarketDetailed Quotes
ORGS Orgenesis
Watchlist
1.235
+0.015+1.23% Trading 05/31 11:34 ET
1.240High1.235Low524Volume
1.240Open1.220Pre Close643.00Turnover0.00%Turnover RatioLossP/E (TTM)35.00MMarket Cap2.64052wk HighLossP/E (Static)28.34MShares0.98052wk Low1.27P/B32.56MFloat Cap16.800Historical High--Dividend TTM26.36MShs Float0.980Historical Low--Div YieldTTM0.41%Amplitude1.227Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Company
Orgenesis, Inc. is a biotechnology company, which engages in the development, manufacturing, and provision of technologies, and services in the cell and gene therapy industry. It operates through the Morgenesis and Therapies segments. The Morgenesis segment refers to the POCare services. The Therapies segment is involved in therapeutic development operations. The company was founded by Sarah Ferber on June 5, 2008 and is headquartered in Germantown, MD.
Revenue Breakdown
Business
Unit:USD
NameYOYOperating income%
Morgenesis--35.17M97.62%
Therapies--6.43M17.85%
Eliminations---5.58M-15.48%
News
Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis
GERMANTOWN, Md., May 30, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapi
Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts From TheraCell Laboratories-backed Master's Program
GERMANTOWN, Md., May 22, 2023 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ:ORGS) ("Orgenesis" or the "Company"), a global biotech company working to unlock the full potential of cell and gene therapies (CGTs), today
Orgenesis to Participate in Benchmark's 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023
Comments
1
1
Kelvin Seetoh’s favourite stock
$Orgenesis(ORGS.US$ so what’s Kelvin Seetoh’s comments now on this stock’s decline? I thought he was super confident of this stock?
2
Read more